Advertisement
BIO vs QGEN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and QGEN is a StrongBuy.
BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 69 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Aroon Indicator for QGEN shows an upward move is likely
QGEN's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 192 similar instances where the Aroon Indicator showed a similar pattern. In 102 of the 192 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 53%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where QGEN advanced for three days, in 140 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
Bearish Trend Analysis
The 10-day RSI Indicator for QGEN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 13 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 69 cases where QGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QGEN as a result. In 42 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 45%.
The Moving Average Convergence Divergence Histogram (MACD) for QGEN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 24 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
QGEN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.095) is normal, around the industry mean (67.298). P/E Ratio (25.318) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (1.201) is also within normal values, averaging (3.473). QGEN's Dividend Yield (0.028) is considerably higher than the industry average of (0.002). P/S Ratio (4.255) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. QGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
BIO | QGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 95 | |
SMR RATING 1..100 | 87 | 65 | |
PRICE GROWTH RATING 1..100 | 15 | 38 | |
P/E GROWTH RATING 1..100 | 2 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
QGEN's Valuation (6) in the Medical Specialties industry is significantly better than the same rating for BIO (90). This means that QGEN’s stock grew significantly faster than BIO’s over the last 12 months.
QGEN's Profit vs Risk Rating (95) in the Medical Specialties industry is in the same range as BIO (100). This means that QGEN’s stock grew similarly to BIO’s over the last 12 months.
QGEN's SMR Rating (65) in the Medical Specialties industry is in the same range as BIO (87). This means that QGEN’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (15) in the Medical Specialties industry is in the same range as QGEN (38). This means that BIO’s stock grew similarly to QGEN’s over the last 12 months.
BIO's P/E Growth Rating (2) in the Medical Specialties industry is in the same range as QGEN (32). This means that BIO’s stock grew similarly to QGEN’s over the last 12 months.
| BIO | QGEN | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 41% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 55% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 59% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 55% |
| Advances ODDS (%) | 3 days ago 65% | 7 days ago 53% |
| Declines ODDS (%) | 1 day ago 69% | 1 day ago 50% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 49% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green while QGEN’s FA Score has 2 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- QGEN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while QGEN’s TA Score has 2 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 4 bearish.
- QGEN’s TA Score: 2 bullish, 6 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +1.58% price change this week, while QGEN (@Medical Specialties) price change was -1.04% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.63%, and the average quarterly price growth was -1.72%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.83%. For the same industry, the average monthly price growth was -5.05%, and the average quarterly price growth was +38.36%.
Reported Earning Dates
BIO is expected to report earnings on Feb 18, 2027.
QGEN is expected to report earnings on Feb 09, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.76% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.83% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
QGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, QGEN has been loosely correlated with BRKR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if QGEN jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To QGEN | 1D Price Change % | ||
|---|---|---|---|---|
| QGEN | 100% | -0.42% | ||
| BRKR - QGEN | 58% Loosely correlated | +0.27% | ||
| BIO - QGEN | 54% Loosely correlated | -0.12% | ||
| RGEN - QGEN | 49% Loosely correlated | -0.78% | ||
| ALC - QGEN | 45% Loosely correlated | -2.16% | ||
| STE - QGEN | 45% Loosely correlated | -0.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OILU | 47.62 | 2.60 | +5.78% |
| MicroSectors Oil & Gas Exp. & Prod. 3x Leveraged ETN (OILU) | |||
| FAI | 50.72 | 1.35 | +2.73% |
| First Trust Exchange-Traded Fund II | |||
| JHEM | 37.64 | 0.69 | +1.87% |
| John Hancock Multifactor Emerging Markets ETF (JHEM) | |||
| UUPP | 25.17 | N/A | N/A |
| Principal CLO ETF (UUPP) | |||
| VCSH | 77.47 | -0.07 | -0.09% |
| Vanguard Short-Term Corporate Bond ETF (VCSH) | |||